UNICA IRIS Institutional Research Information System

ZUDDAS, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 98.416
NA - Nord America 7.565
AS - Asia 1.111
OC - Oceania 29
SA - Sud America 15
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 2
Totale 107.141
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 96.144
US - Stati Uniti d'America 7.504
UA - Ucraina 744
CN - Cina 663
SE - Svezia 488
GB - Regno Unito 300
SG - Singapore 238
DE - Germania 235
FI - Finlandia 189
FR - Francia 143
VN - Vietnam 81
CA - Canada 47
NL - Olanda 41
IN - India 37
AU - Australia 29
RU - Federazione Russa 26
HK - Hong Kong 23
CH - Svizzera 18
BE - Belgio 17
ES - Italia 16
IR - Iran 13
KR - Corea 13
TR - Turchia 12
BR - Brasile 11
DK - Danimarca 8
IL - Israele 8
NO - Norvegia 8
RO - Romania 8
JO - Giordania 7
CR - Costa Rica 5
IE - Irlanda 5
PT - Portogallo 5
MX - Messico 4
PL - Polonia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
EU - Europa 3
JP - Giappone 3
PK - Pakistan 3
AT - Austria 2
CL - Cile 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
GR - Grecia 2
MT - Malta 2
SA - Arabia Saudita 2
SM - San Marino 2
AL - Albania 1
BD - Bangladesh 1
BZ - Belize 1
EE - Estonia 1
JM - Giamaica 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
MU - Mauritius 1
PA - Panama 1
SI - Slovenia 1
Totale 107.141
Salva come PNG Salva come JPEG
Città #
Cagliari 88.620
Uta 5.264
Fairfield 921
Woodbridge 846
Chandler 596
Houston 568
Boardman 536
Ashburn 472
Ann Arbor 444
Jacksonville 390
Wilmington 384
Seattle 348
Nyköping 342
Cambridge 293
Milan 200
Rome 197
Boston 141
Nanjing 121
Dearborn 112
Singapore 107
Beijing 91
Santa Clara 89
Dong Ket 80
Helsinki 73
Shanghai 63
San Diego 61
Redwood City 53
Padova 47
Shenyang 45
Charleston 40
Nanchang 38
Verona 35
Guangzhou 31
Turin 30
Bari 29
Toronto 28
Changsha 27
Hebei 27
Sassari 27
Jiaxing 26
Norwalk 25
New York 24
London 23
Los Angeles 23
Washington 22
Florence 20
Orange 20
Tianjin 20
Jinan 18
Pune 17
Auburn Hills 16
Ningbo 16
Naples 15
Palermo 15
Bologna 14
Sydney 14
Zhengzhou 14
Catania 13
Falls Church 12
Genoa 12
Torino 12
Atlanta 11
Brescia 11
Brussels 11
Messina 11
Mountain View 11
Parma 11
Saint Petersburg 11
Chicago 10
Nuremberg 10
Redmond 10
Vicenza 10
Frankfurt am Main 9
Kunming 9
Amsterdam 8
Las Vegas 8
Livorno 8
Perugia 8
Stockholm 8
Venice 8
Amman 7
Busto Arsizio 7
Casale Monferrato 7
Castelverde 7
Faenza 7
Fidenza 7
Hangzhou 7
Montepulciano 7
Monza 7
Pescara 7
Phoenix 7
Pisa 7
Rimini 7
Taizhou 7
Venezia 7
Borås 6
Casavatore 6
Central 6
Manchester 6
Mumbai 6
Totale 102.525
Salva come PNG Salva come JPEG
Nome #
Child and Adolescent Behavior Inventory (CABI): Standardization for age 6-17 years and first clinical application 1.905
Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: The Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study 1.764
Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder 1.754
Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate 1.611
Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder 1.536
Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine 1.503
Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence 1.485
Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale 1.466
Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis 1.422
Cognitive training for attention-deficit/hyperactivity disorder: Meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials 1.413
Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD) 1.390
Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives 1.368
Development and psychometric properties of the Suicidality: Treatment Occurring in Paediatrics (STOP) Suicidality Assessment Scale (STOP-SAS) in children and adolescents 1.368
The Italian autism network (ITAN): A resource for molecular genetics and biomarker investigations 1.305
Effects of methylphenidate on height in ADHD children. The monitoring of bone age within the ADDUCE project 1.290
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe 1.245
Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder 1.209
ADHD and hyperkinetic disorder 1.168
Corrigendum: Child and adolescent behavior inventory (CABI): A new instrument for epidemiological studies and pre-clinical evaluation 1.168
null 1.153
ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group 1.136
Effects of long-term methylphenidate use on growth and blood pressure: Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) 1.136
Re-thinking treatment targets in child and adolescent psychiatry 1.130
null 1.045
Pediatric acute-onset neuropsychiatric syndrome: A data mining approach to a very specific constellation of clinical variables 1.018
null 980
Psychosocial risk factors for suicidality in children and adolescents 978
Methylphenidate long-term effects on psychiatric outcomes in a Sardinian ADHD population: preliminary results from the prospective ADDUCE project 934
A neurodevelopment approach for a transitional model of early onset schizophrenia 822
1H-NMR-Based Metabolomics in Autism Spectrum Disorder and Pediatric Acute-Onset Neuropsychiatric Syndrome 795
Artificial neural networks analysis of polysomnographic and clinical features in pediatric acute-onset neuropsychiatric syndrome (Pans): From sleep alteration to “brain fog” 773
Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies 771
null 754
null 749
CRS-R. Conners’ Rating Scales. Revised. Manuale 746
Erratum to: Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: A systematic review of head-to-head studies[ BMC Psychiatry. (2013)13, 237] 745
Systematic Review and Meta-analysis: Screening Tools for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents 705
null 699
null 688
Metabolomic Characterization of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) 683
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial 678
Prevalence and correlates of mental disorders among adolescents in Italy: The PrISMA Study 676
null 675
null 665
null 658
Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply 641
null 632
null 603
null 595
null 588
null 581
null 581
null 568
The poor outcome of conduct disorders: a need for innovative, more effective therapeutic interventions 565
null 564
Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis 563
The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG) 563
Neuropsychological characterization of aggressive behavior in children and adolescents with cd/odd and effects of single doses of medications: The protocol of the matrics_wp6-1 study 563
Identifying Neurobiological Markers in Obsessive–Compulsive Disorder: A Study Protocol for a Cross-Sectional Study in Subgroups of Differing Phenotype 558
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis 552
null 549
The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication? 545
null 536
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study 528
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial 522
Profili cognitivi e disturbi psicopatologici. Evidenze neurobiologiche, diagnosi, trattamento 519
null 519
null 517
Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children 511
null 506
Increased Response-Time Variability Across Different Cognitive Tasks in Children With ADHD 503
null 501
null 501
null 497
null 491
A crucial role for basic emotion awareness in the development of emotion regulation? 489
I Disturbi depressivi in età evolutiva 484
Methylphenidate effects on height and bone age in ADHD children. 24 month follow up within the prospective ADDUCE project 483
null 477
Eziologia 475
Association of Risk of Suicide Attempts With Methylphenidate Treatment 469
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents 468
null 467
Clinical characteristics, neuroimaging findings, and neuropsychological functioning in attention-deficit hyperactivity disorder: Sex differences 454
Use of atomoxetine in patients with attention-deficit hyperactivity disorder and comorbid conditions 453
The neuropsychological characterization of aggressive behaviour in children and adolescents with CD/ODD: preliminary results from a multicentric case-control study (MATRICS_consortium) 448
null 444
The MTA at 8 443
Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design 434
null 428
Management and treatment of attention-deficit/hyperactivity disorder 425
The quality of life of children with attention deficit/hyperactivity disorder: a systematic review 409
EFFICACY STUDY OF AN OMEGA-3/6 COMBINATION FOR MILD- TO MODERATE-INATTENTIVE ADHD: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN ITALIAN CHILDREN 408
European clinical guidelines for hyperkinetic disorder - first upgrade 405
null 400
null 399
Non-pharmacological interventions for Attention-Deficit/Hyperactivity Disorder: Systematic review and meta-analyses of randomised controlled trials of dietary and psychological treatments 389
null 379
Plasma poly-unsatured fatty acids profile in children with inattentive ADHD - preliminary results of an efficacy Italian study with omega 3/6 378
null 378
Totale 76.510
Salva come PNG Salva come JPEG
Categoria #
all - tutte 148.992
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 148.992
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010.194 0 0 0 0 3.549 2.340 1.909 538 444 340 479 595
2020/202116.858 777 510 925 3.862 3.262 1.867 1.869 953 511 590 483 1.249
2021/20227.717 573 518 324 892 763 432 371 602 813 872 740 817
2022/202314.642 1.096 1.876 1.615 1.119 1.080 1.161 683 1.973 984 874 1.515 666
2023/202417.145 834 685 636 1.068 1.981 2.656 2.826 1.023 853 1.235 1.807 1.541
2024/202526.398 5.788 8.957 5.420 4.393 1.840 0 0 0 0 0 0 0
Totale 107.613